370 Index Name Paper ref. Name Paper ref. Su, Y Wed 322, Thu 445 Suarez Gonzalez, ME Tue 197 Suárez, C Thu 271 Suarez, E Wed 111 Suarez-Kurtz, G W16.2 Subedi, GP Tue 023 Subramaniam, SR Mon 413 Suda, M Tue 373 Sudano, I FC16.1.2 Suddhasthira, T Thu 443 Sudharmarajan, S Thu 393 Sudo, G Tue 162 Sudo, K Tue 380 Sudo, R Tue 162 Suemaru, K Thu 421 Süverkrüp, R Mon 384 Sugamori, K Tue 389 Sugawara, A Tue 153 Sugihara, M Thu 038 Sugihara, T Mon 335 Sugimoto, M W23.4, Tue 473 Sugimoto, T Thu 260 Sugimoto, Y Tue 294 Sugiyama, A Tue 126, Tue 236, FC13.2.5 Sugiyama, K Mon 177, Mon 182 Sui, Z Tue 173, Tue 325 Suilamo, S Mon 256 Suissa, S FC04.1.1 Sukasem, C Tue 127 Sukoyan, GV Mon 216 Sukumaran, P Thu 079 Sulaiman, SA Tue 455 Sulayman, D-HD FC12.2.1 Suling, F Tue 021 Suljagic, V Tue 091 Sultan, E Mon 203, Mon 201, Mon 205, Mon 204, Mon 202 Sumak, T Tue 030, Tue 031 Summers, RJ W01.1.1, Wed 063, Mon 395, Thu 059, Wed 080, W14.2 Sun, A Tue 138, Mon 457, Mon 458 Sun, B Mon 031 Sun, D Thu 298 Sun, H FC16.3.2, Thu 092, Tue 181 Sun, H-L Thu 172 Sun, H-S W28.1 Sun, JH Tue 297 Sun, L Tue 187, Tue 186 Tue 159, Tue 297, Wed 259 Sun, Y Tue 181 Sung, M-H FC18.4.2 Surber, C Tue 438 Surratt, C Tue 059 Susumu, N Tue 311 Suziedelis, K Mon 403 Suzuki, F Thu 046 Suzuki, H Thu 403 Suzuki, K Tue 435, Thu 250 Suzuki, M Tue 244 Suzuki, T Tue 435, Wed 065, Thu 188 Suzuki, Y Thu 102 Svalbe, B Tue 141, Thu 189 Svard, J Thu 442 Svensson, S Thu 074 Svensson, TH FC17.2.4 Svinarov, D Tue 128 Svirina, D Mon 429 Svirskis, S Mon 429, Wed 045, Tue 253 Svoboda, Z Tue 056 Switzer, C FC09.3.3 Sy, GY W27.5 Sychev, DA Tue 129, Tue 057, Thu 253 Syed, S Tue 495 Sylte, I Mon 224 Syunyakov, S Tue 024 Syyong, H Wed 228 Szabó, B Mon 150, Mon 167 Szabo, C FC15.3.6, FC15.4.2, Thu 202 Szabó, G Thu 307 Szabo, S W02.2.2, W02.2.7, Tue 466 Szafir, D W10.4 Szakacs, B Mon 283 Szarek, WA Tue 414, Szczepazka, R Wed 279 Szekeres, T Thu 308 Szell, T Mon 100 Szente, L FC16.2.6 Szentirmay, É Tue 078 Szilagyi, K Thu 033 Szilvássy, Z Mon 163, Tue 128, Tue 125, Mon 150, Mon 167, Tue 142 Szitter, I Tue 271, Mon 283 Szõke, E FC16.2.6, W19.3, Tue 250, Mon 283, Mon 106, Mon 401 Szolcsányi, J Tue 271, Mon 283Mon 110, Tue 078, Mon 401, Mon 318 Sztojkov-Ivanov, A Tue 130 Szulc, M Thu 174 Szuts, T Tue 250 Szymanski, J Tue 313, Tue 131, Wed 119 Tabassum, F Mon 260, Wed 315 Tabatabaei Naeini, A Tue 370 Taché, Y W02.3.2 Tachikawa, E Tue 477 Tada, Y Tue 067, Tue 143 Tadagaki, K Thu 078 Taddio, A FC10.5.3 Taegtmeyer, H FC05.2.1 Tagliaferro, P Thu 176 Tagwireyi, D Tue 004 Taha, H Tue 444 Tahara, Y Mon 173, Tue 122 Taher, A FC01.3.4 Tahmiscija, I Wed 171 Tai, WCS Thu 296 Taillon, I Wed 123 Taimi, V FC09.1.5 Taira, E Wed 186, Tue 477 Tajti, J Mon 106 Tajuba, J Thu 021, Tue 221 Takada, M Tue 136 Takahama, K Tue 167 Takahara, A Tue 168 Takahara, A Thu 260 Takahashi, H Tue 272 Takahashi, HK Mon 035, Mon 329, Thu 275 Takahashi, K Tue 072, Thu 072 Takahashi, R Tue 156
Name Paper ref. Name Paper ref. Takahashi, T Tue 077 Takahashi, Y Thu 320 Takahashi-Yanaga, F Tue 162 Takahasi, Y Tue 373 Takai, M Thu 103 Takamura, E Thu 227 Takano, K Thu 286, FC09.1.6 Takano, Y Thu 108, Wed 223, Mon 309, FC09.1.6 Takarada, T Mon 441 Takashima, H Tue 459 Takashima, T Tue 244 Takashima-Hirano, M Tue 244 Takashina, Y Tue 484, Tue 491 Takatori, S Tue 154, Thu 261, Tue 415 Takatsuki, M Mon 307 Takayama, S Mon 335 Takayanagi, S Tue 153 Takeba, Y Wed 117, Tue 273, Tue 337, Tue 483 Takechi, K Thu 421 Takeda, H Thu 422, Thu 423, Thu 397 Takeda, K Thu 260 Takenoshita, S Wed 117 Takenoshita-Nakaya, S Tue 337, Tue 483 Takeuchi, K Tue 379, Mon 179, W23.1, Tue 262, Mon 335, Mon 255, Mon 405, Tue 236, W02.2.3, Tue 467, Thu 262 Takeuchi, K Thu 072, Tue 274, W02.2.4 Takeuchi, O PL14 Takeuchi, Reiri Tue 432 Takeuchi, S Tue 318, Tue 138 Takeuchi, T Thu 423, Thu 422, Thu 397 Takeya, K Wed 239 Takeyama, M Tue 132 Takir, S Thu 269 Takuma, K Tue 060, Tue 360 Talani, G Thu 190, Tue 133 Talari, H Thu 209 Talbot, S Thu 073 Talbot, S Tue 275 Talebi, M Mon 454 Talja, M Thu 223 Tallerova, A Tue 276 Talman, V Tue 433 Tam, C Thu 197 Tam, CWY Tue 140 Tamae, A Tue 243 Tamaki, T Mon 180, Wed 247 Tamargo, J FC06.3.2 Tamariz, J Wed 217 Tamashiro, WMSC Mon 289 Tamba, B Mon 108 Tamba, BI Tue 134 Tambo, Ernest YI.09 Tamm, J Thu 427 Tammaro, P Tue 061 Tamminen, T Mon 341 Tampé, R FC02.2.1 Tamuleviciute, A Tue 061 Tamura, E Thu 204 Tamura, H Tue 474 Tamura, Y Tue 236 Tan, C Thu 074 Tan, H-M FC16.4.5 Tan, KL Tue 434 Tan, PCS Mon 389 Tan, SC Tue 153, Thu 181 Tanabe, M Mon 272 Tanabe, S Tue 435 Tanabe, T FC03.4.5 Tanabe, Y Thu 248 Tanae, M Thu 355 Tanaka, A Mon 405 Tanaka, H Wed 186, Tue 168, Thu 099, Thu 260, Tue 373, Mon 461 Tanaka, M Tue 380, Tue 492, Wed 117 Tanaka, N Thu 263, Tue 375 Tanaka, S Wed 422, Wed 415 Tanaka, Y Thu 108, Tanayen, JK Tue 209 Tancharoen, S Thu 331, Thu 443 Tandon, N Mon 169 Tandon, S FC01.3.6 Tang, H-S Wed 430 Tang, L FC06.4.6, Mon 210, Wed 362, Wed 258, Tue 317, Thu 298 Tang, SP Tue 455 Tang, X FC12.2.5 Tanigami, M Mon 255 Tanigawara, Y Tue 311 Tanii, H Tue 413 Tanji, H Mon 313 Tantisira, B Thu 356, Thu 357 Tantisira, M Thu 356, Thu 357 Tao, P-L Tue 135 Tao, S Tue 152 Tapaninen, T Tue 062 Tapia-Pancardo, DC Tue 025 Tarasov, SA Mon 284 Taraz, M Tue 251 Tardieu, J-L Thu 035 Targonska, A Thu 291 Tashiro, M Tue 166, Tue 484, FC17.5.6 Taskinen, P Tue 166 Tateishi, T Wed 127 Taube, C FC09.1.2 Tavares, F Mon 376 Tavares, JJF Thu 352 Tavares, PLF Tue 282 Tavridou, A Tue 224, Mon 187 Tay, Jolyn Tue 136 Tayarani-Najaran, Z Thu 313, Tue 424, Thu 342 Tayebi, H Mon 160 Taylor, DA Wed 428 Taylor, D Thu 191 Taylor, M FC05.3.6 Taylor, P Mon 353, Mon 352 Taylor, R W06.3 Techanaparukse, K Wed 374, Tedroff, J Wed 147 Tee, LBG Tue 063 Teft, W Tue 064 Teixeira, M FC03.1.5, W31.4 Teixeira, S Tue 232 Teja-Isavadharm, P Tue 090 Index 371
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289:
FC11 G protein-coupled 7TM receptor
- Page 290 and 291:
FC13 Maximising benefits and minimi
- Page 292 and 293:
FC13 Maximising benefits and minimi
- Page 294 and 295:
W29 New horizons in therapeutic dru
- Page 296 and 297:
FC14 Addiction and doping: Neurobio
- Page 298 and 299:
FC15 Endothelium in health and dise
- Page 300 and 301:
FC15 Endothelium in health and dise
- Page 302 and 303:
FC15 Endothelium in health and dise
- Page 304 and 305:
FC16 Natural products: Past and fut
- Page 306 and 307:
FC16 Natural products: Past and fut
- Page 308 and 309:
FC16 Natural products: Past and fut
- Page 310 and 311:
FC16 Natural products: Past and fut
- Page 312 and 313:
FC17 New approaches and targets in
- Page 314 and 315:
FC18 Nuclear receptor targets for t
- Page 316 and 317:
314 Index Name Paper ref. Name Pape
- Page 318 and 319:
316 Index Name Paper ref. Name Pape
- Page 320 and 321:
318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 380 and 381: 378 Index Name Paper ref. Name Pape
- Page 382 and 383: 380 Index Name Paper ref. Name Pape
- Page 384 and 385: 382 Notes Notes
- Page 386: Final Programme printed in Singapor